Stockwatch: AD-a-MAb-a-do, AD-a-MAb-a-done
This article was originally published in Scrip
Executive Summary
Investors' attention will be drawn on Tuesday September 11th to the Congress of the European Federation of Neurological Societies (EFNS) in Stockholm when the post mortem of the full data from the failed phase III studies of Elan, Pfizer and Johnson & Johnson's (J&J) monoclonal antibody against beta-amyloid (bapineuzumab) in Alzheimer's Disease (AD) will be presented.